CSV September 18, 2022 through September 18, 2024 See all Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MESO-	CHEMICAL	*USPNF Online*	Online	27-Jan-2023	1-Jun-2023	*NA*	*NA*	Change

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ZEAXANTHIN	INFORMATION							(3*R*,3?*S*-*meso*)-Zeaxanthin to: (3*R*,3?*S*)-Zeaxanthin
MAGNESIUM OXIDE	IM PURITIES/*Limit of Calcium*	*USPNF Online*	Online	25-Feb-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of Magnesium Hydroxide in the *Sample solution* (mg/mL) to: C_U = concentration of Magnesium Oxide in the *Sample solution* (mg/mL)
MAFENIDE ACETATE FOR TOPICAL SOLUTION	IM PURITIES/*Organic Impurities*	*USPNF Online*	Online	16-Dec-2022	1-Jan-2023	*NA*	*NA*	In *System suitability*: Change **Samples**: *System suitability solution*, *Standard solution A*, and *Standard*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution B to: **Samples**: *System suitability solution* and *Standard solution A* AND In *Analysis*: Change **Samples**: *Mobile phase*, *Standard solution A*, and *Sample solution* Chromatograph the *Standard solution* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection. to: **Samples**: *Mobile phase*, *Standard*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution A, *Standard solution B*, and *Sample solution* Chromatograph *Standard solution B* and adjust the integration parameters so that the response is 5%–15% of full-scale deflection.
LYSINE HYDROCHLORIDE	IMPURITIES/*Related Compounds*	*USPNF Online*	Online	16-Dec-2022	1-Jun-2023	*NA*	*NA*	In *Chromatographic system*/*Spray reagent*: Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(95:5)
LYSINE ACETATE	IM PUR ITIES/*Related Compounds*	*USPNF Online*	Online	16-Dec-2022	1-Jun-2023	*NA*	*NA*	In *Chromatographic system*/*Spray reagent*: Change 0.2 g of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5) to: 2 mg/mL of ninhydrin in a mixture of butyl alcohol and 2 N acetic acid (95:5)
LINEZOLID TABLETS	IM PUR ITIES/*Organic Impurities*	*USPNF Online*	Online	26-May-2023	1-Jun-2023	*NA*	*NA*	In *Sensitivity solution*: Change 0.5 ug/mL of USP Linezolid RS from *Standard solution* in *Diluent* to: 0.5 ?g/mL of USP Linezolid

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LINEZOLID TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	26-Jan-2024	1-Feb-2024	*NA*	*NA*	RS from *Standard solution* in *Diluent* In *Dissolution* ?711?/*Test 1*/*Analysis*: Change Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL

Monograph Title	Section Sort ascending	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								L = label claim (mg/Tablet) to: Result = $(r_U/r_S) \times C_S \times V \times (1/L) \times D \times 100$ r_U = peak response of linezolid from the *Sample solution* r_S = peak response of linezolid from the *Standard solution* C_S = concentration of USP Linezolid RS in the *Standard solution* (mg/mL) V = volume of *Medium*, 900 mL L = label claim (mg/Tablet) D = dilution factor of the *Sample*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution, as needed
LIDOCAINE, RACEPINEPHRINE AND TETRACAINE HYDROCHLORIDES COMPOUNDED TOPICAL GEL	DEFINITION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	Change Prepare Lidocaine, Racepinephrine, and Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Sterile Preparations* <797>). to: Prepare Lidocaine, Racepinephrine, and

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Tetracaine Hydrochlorides Compounded Topical Gel containing 40 mg/mL of lidocaine hydrochloride, 1 mg/mL of racepinephrine hydrochloride, and 10 mg/mL of tetracaine hydrochloride as follows (see *Pharmaceutical Compounding—Nonsterile Preparations* <795>).
LIDOCAINE HYDROCHLORIDE AND DEXTROSE INJECTION	*Assay for lidocaine hydrochloride*	*USPNF Online*	Online	24-Feb-2023	1-Mar-2023	*NA*	*NA*	Change Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine and Epinephrine Injection*.

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Proceed with Injection as directed in the *Assay for lidocaine hydrochloride* under *Lidocaine Hydrochloride and Epinephrine Injection.*
LIDOCAINE	ASSAY	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Procedure*: Change **Column:** 3.9-mm × 30-cm; 4-µm packing L1 to: **Column:** 3.9-mm × 30-cm; 10-µm packing L1
LEVORPHANOL TARTRATE TABLETS	PERFORMANCE TESTS/ *Uniformity of Dosage Units* ?905?	*USPNF Online*	Online	31-Mar-2023	1-Aug-2023	*NA*	*NA*	In *Sample solution*: Change Nominally about 80 ug/mL of levorphanol tartrate in

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluent prepared as follows. to: Nominally about 80 µg/mL of levorphanol tartrate in *Diluent* prepared as follows.
LATANOPROST	ASSAY/ *Procedure*	*USPNF Online*	Online	29-Jul-2022	1-Dec-2022	*NA*	*NA*	Change **Standard solution**: Transfer 2.0 mg/mL of USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. **Sample solution**

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								: Transfer 2.0 mg/mL of Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume. to: **Standard solution**: 2.0 mg/mL of USP Latanoprost RS prepared as follows. Transfer USP Latanoprost RS into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								20% of the final volume, and dilute with chro matographic hexane to volume. **Sample solution**: 2.0 mg/mL of Latanoprost prepared as follows. Transfer Latanoprost into a suitable volumetric flask, dissolve in dehydrated alcohol equivalent to 20% of the final volume, and dilute with chro matographic hexane to volume.
LANSOPRAZOLE DELAYED-RELEASE CAPSULES	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	30-Sep-2022	1-Oct-2022	*NA*	*NA*	Delete **Blank**: Methanol and *Diluent* (1:9)

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOSORBIDE MONONITRATE TABLETS	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	In *Organic Impurities*/*Standard solution*: Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In *System suitability*/*Suitability requirements*/*Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In four

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mononitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to: Isosorbide mononitrate related compound A
ISOFLURANE	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Analysis*: Change Result = $(r_U/r_S) \times C_S \times (1/F)$ to: Result = $(r_U/r_S) \times C_F \times (1/F)$ AND Change C_S = final concentration of

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ISOBUTYL ALCOHOL	ASSAY/ *Procedure*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	USP Isoflurane Related Compound B RS in the *Standard solution* (%) to: C_F = final concentration of USP Isoflurane Related Compound B RS in the *Standard solution* (%) In *Analysis*: Change r_S = sum of all the peaks except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution* to: r_T = sum of all the peaks

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								except those each of which with an area less than 0.1 times the area of the major peak from the *Reference solution*
IPRATROPIUM BROMIDE INHALATION SOLUTION	IMPURITIES	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *Organic Impurities*: Change **Column:** 4.6-mm × 25-µm; 5-µm packing L1 to: **Column:** 4.6-mm × 25-cm; 5-µm packing L1
IODIXANOL INJECTION	IMPURITIES	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *Organic Impurities, Procedure 2*/footnote 4: Change 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl](acetylimino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]carbonyl]amino]-2-hy droxypropyl]oxy]-2-hydroxypropyl](acetylimino)]-*N*,*N*'-bis(2,3-dihy droxypropyl)-2,4,6-triiodo-1,3-benzendicarboxamide. to: 5-[[3-[[3-[[[3-[[3-[[3,5-Bis-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl](acetylamino)]-2-hydroxypropyl](acetylamino)]-5-[[[2,3-dihydroxypropyl]amino]carbonyl]-2,4,6-triiodophenyl]

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								carbonyl]amino]-2-hydroxypropyl]oxy]-2-hydroxypropyl](acetylamino)]-*N*,*N*'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide.
IODIXANOL INJECTION	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In *USP Reference Standards* ?11?/USP Iodixanol Related Compound E RS: Change 5-[[3-[[3-[[(2,3-Dihydroxypropyl)amino]carbonyl]-5- [[amino]carbonyl]-2,4,6-triiodophenyl](acetylimino)]-2-hydroxypropyl]-(acetylimino)]-N,N?-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide.

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 5-{*N*-[3-(*N*-{3-Carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N^1,N^3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide.
GLYCYL-L-TYROSINE	IMPURITIES/*Related Compounds*	*USPNF Online*	Online	24-Feb-2023	1-Jun-2023	*NA*	*NA*	In *Buffer solution*: Change Dissolve 6.84 g of potassium phosphate in 1000 mL of water. to: Dissolve 6.84 g of monobasic potassium phosphate in 1000 mL of water.
GLUCAGON	PROCESS-RELATED	*USPNF Online*	Online	29-Dec-2023	1-Jan-2024	*NA*	*NA*	In *Acetic Acid in Peptid*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	IMPURITIES AND OTHER COMPONENTS							*es/Analysis*: Change C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (mg/mL) to: C_{SPA} = concentration of potassium acetate in each of the *Standard solutions* (µg/mL) AND In *Am monium/ Analysis*: Change C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (mg/mL) to:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								C_{SAC} = concentration of ammonium chloride in each of the *Standard solutions* (µg/mL)
FOSAMPRENAVIR CALCIUM TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	25-Aug-2023	1-Sep-2023	*NA*	*NA*	In *Dissolution* ?711?/*Medium*: Change 26.7 g/L of sodium acetate trihydrate in water. Add 133 mL of glacial acetic acid to this solution, and then dilute with water to 10 L; 900 mL. to: 0.02 M sodium acetate buffer, pH 3.5, prepared as follows. Dissolve 2.67 g of sodium acetate in 100 mL of water. Add 13.3 mL of

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								glacial acetic acid and then dilute with water to 1000 mL; 900 mL.
FLUVOXAMINE MALEATE TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Solution A*: Change 8 g/L of 1-pentanesulfonic acid sodium salt and 1 g/L of monobasic potassium phosphate in water. to: 8 g/L of 1-pentanesulfonic acid sodium salt and 1.1 g/L of monobasic potassium phosphate in water.
FLUTICASONE PROPIONATE NASAL SPRAY	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	27-Jan-2023	1-Feb-2023	*NA*	*NA*	In *Analysis*: Change Samples: *System suitability solution*, *Identification*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution, and *Sample solution* to: Samples: *Identification solution* and *Sample solution*
FLUTICASONE PROPIONATE NASAL SPRAY	OTHER COMPONENTS/*Content of Phenylethyl Alcohol*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Sample solution*: Change Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40 mL of *Diluent*, and sonicate for 10 min until the supernatant is clear. Use the clear supernatant for analysis. to: Transfer 1.0 g of the Nasal Spray to a 50-mL volumetric flask. Add about 40

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								mL of *Diluent*, and sonicate for 10 min. Dilute with *Diluent* to volume, and shake. Allow to stand for 10 min until the supernatant is clear. Use the clear supernatant for analysis.
FLURAZEPAM HYDROCHLORIDE	USP REFERENCE STANDARDS ?11?	*USPNF Online*	Online	23-Feb-2024	1-Mar-2024	*NA*	*NA*	In USP Flurazepam Related Compound C RS: Change 5-Chloro-2-(2-diethylaminoethyl(amino)-2?-fluorobenzophenone hydrochloride. to: 5-Chloro-2-(2-diethylaminoethylamino)-2?-fluorobenzophenone hydrochloride.
FELODIPINE	IM PUR	*USPNF Online*	Online	18-Nov-2022	1-Dec-2022	*NA*	*NA*	Change **Buffer**, **Mobile**

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities*							**phase**, **System suitability solution**, **Standard solutio n**, **Sample solution**, and **Chromatograp hic system**: Proceed as directed in the *Assay*. to: **Buffer**, **Mobile phase**, **System suitability solution**, **Standard solutio n**, **Sample solution**, and **Chromatograp hic system**: Proceed as directed in the *Assay*, and use 40 µL injection volume for the *Sensitivity solution*.

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
EXENATIDE INJECTION	PRODUCT-RELATED SUBSTANCES AND IMPURITIES	*USPNF Online*	Online	26-Jul-2024	1-Aug-2024	*NA*	*NA*	In *Procedure*/*Chromatographic system*/*Column*: Change 4.6-mm × 10-cm; 3-µm packing L52 to: 4.6-mm × 10-cm; 3-µm packing L52; two columns in series
ESCITALOPRAM TABLETS	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Buffer*: Change Adjust with 1 N sodium hydroxide VS to a pH of 5.2. to: Adjust with 1 N sodium hydroxide to a pH of 5.2.
ESCITALOPRAM TABLETS	PERFORMANCE TESTS/ *Dissolution*	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	In *Test 1*/*Medium*: Change 0.1 N

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	?711?							hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL AND In *Test 2*/*Medium*: Change 0.1 N hydrochloric acid VS; 900 mL to: 0.1 N hydrochloric acid; 900 mL
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	*Identification*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Proceed as directed in the *Identification* test under *Erythromycin Ethylsuccinate Oral Suspension*, beginning with “Prepare a Standard

Monograph Title	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution.” to: Prepare a Standard solution of USP Erythromycin Ethylsuccinate RS in methanol containing about 3 mg per mL. Apply separately 10 µL each of the test solution and the Standard solution to a suitable thin-layer chromatographic plate (see *Chromatography* ?621?) coated with a 0.25-mm layer of chromatographic silica gel mixture, and allow to dry. Place the plate in an unlined chromatographic

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								chamber, and develop the chromatograms in a solvent system consisting of a mixture of methanol and chloroform (85:15) until the solvent front has moved about 9 cm. Remove the plate from the chamber, mark the solvent front, and allow the solvent to evaporate. Spray the plate with a mixture of dehydrated alcohol, *p* -methoxybenzal dehyde, and sulfuric acid (90:5:5). Heat the plate at 100° for 10 minutes, and

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								examine the chromatograms, in which the erythromycin and succinic acid moieties appear as black-to-purple spots: the R_F values of the principal spots obtained from the test solution correspond to those obtained from the Standard solution.
ERYTHROMYCIN ETHYLSUCCINATE FOR ORAL SUSPENSION	*Assay*	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	Change Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed in the *Assay* under *Erythromycin Ethylsuccinate*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Oral Suspension. to: Constitute Erythromycin Ethylsuccinate for Oral Suspension as directed in the labeling, and proceed as directed for erythromycin under *Antibiotics—Microbial Assays* ?81?, using an accurately measured volume of the reconstituted suspension, freshly mixed and free from air bubbles, blended for 4 ± 1 minutes in a high-speed glass blender jar with sufficient

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								methanol to give a stock solution containing the equivalent of about 1 mg of erythromycin per mL. Dilute this stock solution quantitatively with *Buffer B.3* to obtain a *Test Dilution* having a concentration assumed to be equal to the median dose level of the Standard.
ERYTHROMYCIN DELAYED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution* ?711?	*USPNF Online*	Online	31-Mar-2023	1-Apr-2023	*NA*	*NA*	In *Test 1*: Change **Buffer stage Medium**: 0.05 M pH 6.8 phosphate buffer (see *Reagents, Indicators, and Solutions—Buffe*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								r Solutions) to: **Buffer stage Medium**: 0.05 M pH 6.8 phosphate buffer (see *Reagents, Indicators, and Solutions—Buffer Solutions*); 900 mL
ENZACAMENE	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Dec-2022	*NA*	*NA*	In *Analysis*: Change C_U = concentration of enzacamene in the *Sample solution* (mg/mL) to: C_U = concentration of Enzacamene in the *Sample solution* (mg/mL)
ENSULIZOLE	IDENTIFICATION	*USPNF Online*	Online	29-Mar-2024	1-Apr-2024	*NA*	*NA*	In *B*.: Change The retention time of the

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								major peak of the *Sample solution* exhibits maxima and minima at the same wavelengths as those of the *Standard solution*, as obtained in the *Assay*. to: The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
EDETATE DISODIUM COMPOUNDED OPHTHALMIC SOLUTION	DEFINITION	*USPNF Online*	Online	28-Jun-2024	1-Jul-2024	*NA*	*NA*	In two instances: Change to a pH between 6.5 and 7.5. to:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to a pH between 6.1 and 7.1.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test for dutasteride*/*Tier 2*/*Medium*: Change 10 g/L of cetyltrimethylammonium bromide and 750,000 USP units of activity/mg of pepsin, purified in 0.1 N hydrochloric acid; 900 mL to: Dissolve 10 g of cetyltrimethylammonium bromide and 1.6 g of pepsin, purified in 1000 mL of 0.1 N hydrochloric acid; 900 mL
DUTASTERIDE AND TAMSULOSIN	ADDITIONAL REQUIREMENTS	*USPNF Online*	Online	17-Nov-2023	1-Dec-2023	*NA*	*NA*	In *USP Reference Standards*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HYDROCHLORIDE CAPSULES								?11?/USP Dihydrodutasteride RS: Change *N*-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androst-1-ene-17?-carboxamide. to: *N*-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5?-androstane-17?-carboxamide.
DOXORUBICIN HYDROCHLORIDE INJECTION	ASSAY/ *Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN HYDROCHLORIDE INJECTION	IMPURITIES/*Organic Impurities*	*USPNF 2022 Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Hydrochloride RS (µg/mg) In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP Doxorubicin Hydrochloride RS (µg/mg)
DOXORUBICIN HYDROCHLORIDE FOR INJECTION	ASSAY/*Procedure*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOXORUBICIN HYDROCHLORIDE FOR INJECTION	IMPURITIES/*Organic Impurities*	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Doxorubicin Hydrochloride RS (µg/mg) In *Analysis*: Change *P* = potency of doxorubicin in USP Doxorubicin Hydrochloride RS (µg/mg) to: *P* = potency of doxorubicin hydrochloride in USP
DOXORUBICIN HYDROCHLORIDE	ASSAY	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	Doxorubicin Hydrochloride RS (µg/mg) In *Procedure*/*System suitability solution*: Add link to USP Store for USP Epirubicin Hydrochloride RS
DOXAZOSIN MESYLATE	IMPUR	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	In *Analysis*: Change

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	ITIES/*Organic Impurities*							C_S = concentration of the corresponding USP Doxazosin Related Compound RS or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL) to: C_S = concentration of the corresponding USP Reference Standard or USP Doxazosin Mesylate RS (for calculating unspecified impurities) in the *Standard solution* (mg/mL)

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DOFETILIDE	CHEMICAL INFORMATION	*USPNF Online*	Online	28-Oct-2022	1-Nov-2022	*NA*	*NA*	Change ?-[(*p*-Methanesulfonamidophenethyl)methylamino]methane sulfono-*p*-phenetidide to: *N*-{4-[2-(Methyl{2-[4-(methylsulfonamido)phenoxy]ethyl}amino)ethyl]phenyl}methanesulfonamide
DOCETAXEL	IMPURITIES	*USPNF Online*	Online	31-May-2024	1-Jun-2024	*NA*	*NA*	In *Organic Impurities*, *Procedure 1*: Change **System suitability solution, Standard solution, Sample solution,** and **Chromatographic system:** Proceed as directed in the

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Assay. to: **Mobile phase, Diluent, System suitability solution, Standard solution, Sample solution,** and **Chromatographic system:** Proceed as directed in the *Assay*.
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Dissolution* ?711?/*Test 8*/*Tolerances*: Change The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution* <711>, *Acceptance*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DILUTED ISOSORBIDE MONONITRATE	IMPURITIES	*USPNF Online*	Online	26-Apr-2024	1-May-2024	*NA*	*NA*	*Table 1*. to: The percentage of the labeled amount of valproic acid ($C_8H_{16}O_2$) dissolved at the times specified conform to *Dissolution* <711>, *Acceptance Table 2*. In *Organic Impurities/Standard solution*: Change isosorbide related compound A to: isosorbide mononitrate related compound A AND In *System suitability/Suitability re*

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								quire ments/*Relative standard deviation*: Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In four instances in *Analysis*: Change isosorbide related compound A, to: isosorbide mon onitrate related compound A, AND In *Table 1*: Change Isosorbide related compound A to:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DILTIAZEM HYDROCHLORIDE EXTENDED-RELEASE CAPSULES	IDENTIFICATION	*USPNF Online*	Online	28-Apr-2023	1-May-2023	*NA*	*NA*	Isosorbide mononitrate related compound A Change **A.** The UV-Vis spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*. to: **A.** The UV spectrum of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay*.
DIGOXIN TABLETS	ASSAY	*USPNF Online*	Online	29-Sep-2023	1-Oct-2023	*NA*	*NA*	In *Procedure/Analysis*:

Monograph Title Sort ascending	Section	Source Publication	Page Number	Errata Post Date	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change C_U = nominal concentration of in the *Sample solution* (µg/mL) to: C_U = nominal concentration of digoxin in the *Sample solution* (µg/mL)

Pagination

- First page « First
- Previous page ‹ Previous
- Page 1
- Page 2
- Current page 3
- Page 4
- Page 5
- Next page Next ›
- Last page Last »